Cancer Research and Treatment

Original Articles

Pediatric cancer

The Role of Early and Delayed Surgery for Infants with Congenital Brain Tumors: Jong Seok Lee, Ji Yeoun Lee, Kyung Hyun Kim, Sung-Hye Park, Eun Jung Koh, Seung-Ki Kim, Ji Hoon Phi; Cancer Res Treat. 2024;56(3):909-919. Published online December 28, 2023; DOI: https://doi.org/10.4143/crt.2023.1174

Abstract PDF Supplementary Material PubReader ePub: Purpose
The present study aimed to evaluate the role of early and delayed surgery in congenital brain tumors and analyze the clinical outcomes of infantile brain tumors.
Materials and Methods
We performed a retrospective cohort study on 69 infantile brain tumors at a single institution from January 2008 to June 2023. Outcomes were assessed as early mortality (within 30 days following surgery) to evaluate the risk of early surgery in congenital brain tumors. Outcomes of recurrence and overall survival were analyzed in infantile brain tumors.
Results
Surgery-related early mortality appeared to occur in young and low-body-weight patients. Cut-off values of age and body weight were found to be 1.3 months and 5.2 kg to avoid early mortality. Three patients (3/10, 30%) showed early mortality in the early surgery group, and early mortality occurred in one patient (1/14, 7.14%) in the delayed surgery group, whose tumor was excessively enlarged. Younger age at diagnosis (< 3 months of age; hazard ratios [HR], 7.1; 95% confidence intervals [CI], 1.4 to 35.6; p=0.018) and leptomeningeal seeding (LMS; HR, 30.6; 95% CI, 3.7 to 253.1; p=0.002) were significant independent risk factors for high mortality in infantile brain tumors.
Conclusion
We suggest delaying surgery until the patient reaches 1.3 months of age and weighs over 5.2 kg with short-term imaging follow-up unless tumors grow rapidly in congenital brain tumors. Younger ages and the presence of LMS are independent risk factors for high mortality in infantile brain tumors.

2,469 View
95 Download

CNS cancer

The Role of Postoperative Radiotherapy in Intracranial Solitary Fibrous Tumor/Hemangiopericytoma: A Multi-institutional Retrospective Study (KROG 18-11): Joo Ho Lee, Seung Hyuck Jeon, Chul-Kee Park, Sung-Hye Park, Hong In Yoon, Jong Hee Chang, Chang-Ok Suh, Su Jeong Kang, Do Hoon Lim, In Ah Kim, Jin Hee Kim, Jung Ho Im, Sung-Hwan Kim, Chan Woo Wee, Il Han Kim; Cancer Res Treat. 2022;54(1):65-74. Published online March 24, 2021; DOI: https://doi.org/10.4143/crt.2021.142

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to evaluate the role of postoperative radiotherapy (PORT) in intracranial solitary fibrous tumor/hemangiopericytoma (SFT/HPC).
Materials and Methods
A total of 133 patients with histologically confirmed HPC were included from eight institutions. Gross total resection (GTR) and subtotal resection (STR) were performed in 86 and 47 patients, respectively. PORT was performed in 85 patients (64%). The prognostic effects of sex, age, performance, World Health Organization (WHO) grade, location, size, Ki-67, surgical extent, and PORT on local control (LC), distant metastasis-free survival (DMFS), progression-free survival (PFS), and overall survival (OS) were estimated by univariate and multivariate analyses.
Results
The 10-year PFS, and OS rates were 45%, and 71%, respectively. The multivariate analysis suggested that PORT significantly improved LC (p < 0.001) and PFS (p < 0.001). The PFS benefit of PORT was maintained in the subgroup of GTR (p=0.001), WHO grade II (p=0.001), or STR (p < 0.001). In the favorable subgroup of GTR and WHO grade II, PORT was also significantly related to better PFS (p=0.028). WHO grade III was significantly associated with poor DMFS (p=0.029). In the PORT subgroup, the 0-0.5 cm margin of the target volume showed an inferior LC to a large margin with 1.0-2.0 cm (p=0.021). Time-dependent Cox proportion analysis showed that distant failures were significantly associated with poor OS (p=0.003).
Conclusion
This multicenter study supports the role of PORT in disease control of intracranial SFT/HPC, irrespective of the surgical extent and grade. For LC, PORT should enclose the tumor bed with sufficient margin.

Citations

Citations to this article as recorded by

Development of an MRI‐Based Comprehensive Model Fusing Clinical, Radiomics and Deep Learning Models for Preoperative Histological Stratification in Intracranial Solitary Fibrous Tumor
Xiaohong Liang, Kaiqiang Tang, Xiaoai Ke, Jian Jiang, Shenglin Li, Caiqiang Xue, Juan Deng, Xianwang Liu, Cheng Yan, Mingzi Gao, Junlin Zhou, Liqin Zhao
Journal of Magnetic Resonance Imaging.2024; 60(2): 523. CrossRef
Meningeal Solitary Fibrous Tumor: A Single-Center Retrospective Cohort Study
Siyer Roohani, Yasemin Alberti, Maximilian Mirwald, Felix Ehret, Carmen Stromberger, Soleiman Fabris Roohani, Katja Bender, Anne Flörcken, Sven Märdian, Daniel Zips, David Kaul, Manish Charan
Sarcoma.2024; 2024: 1. CrossRef
Repeated Radiation Therapy of Recurrent Solitary Fibrous Tumors of the Brain: A Medical Case History Over 20 Years
Anna Carla Piccardo, Sabrina Gurdschinski, Sybille Spieker, Christof Renner, Piotr Czapiewski, Markus Wösle, I. Frank Ciernik
Advances in Radiation Oncology.2024; 9(4): 101426. CrossRef
Intracranial solitary fibrous tumors: Clinical, radiological, and histopathological insights along with review of literature
Adil Aziz Khan, Sana Ahuja, Dipanker Singh Mankotia, Sufian Zaheer
Pathology - Research and Practice.2024; 260: 155456. CrossRef
Central nervous system solitary fibrous tumors: Case series in accordance with the WHO 2021 reclassification. Framework for patient surveillance
V. Matthijs, R. Beckers, C. Vanden Broecke, F. Dedeurwaerdere, J. Van Dorpe, D. Vanhauwaert, G. Hallaert
Acta Neurochirurgica.2024;[Epub] CrossRef
Recurrence of Solitary Fibrous Tumor in the Spinal Cord Following Gross Total and Subtotal Resection: A Case Report of Recurrence 19 Years of Post-total Resection and Systematic Literature Review
Satoka SHIDOH, Kazutoshi HIDA, Yoshitaka ODA, Toru SASAMORI, Prabin SHRESTHA, Jangbo LEE, Satoshi YAMAGUCHI
NMC Case Report Journal.2024; 11: 297. CrossRef
The role of radiotherapy in intracranial hemangiopericytoma/solitary fibrous tumors
Nuri Kaydıhan, Gözde Yazıcı, Petek Erpolat, Serra Kamer, Burak Erdemci, Emine Canyılmaz, Beste Melek Atasoy, Dicle Aslan, Ela Delikgöz Soykut, Enis Özyar, Fatih Demircioğlu, Fazilet Öner Dinçbaş, Meltem Kirli Bolukbas, Ramazan Aksu, Selvi Tabak Dinçer, Ya
Strahlentherapie und Onkologie.2024;[Epub] CrossRef
Does Adjuvant Radiotherapy Enhance Survival in Intracranial Solitary Fibrous Tumor Patients?
Sakhr Alshwayyat, Haya Kamal, Tala Abdulsalam Alshwayyat, Mustafa Alshwayyat, Mesk Alkhatib, Ayah Erjan
World Neurosurgery.2024; : 123545. CrossRef
The Role of Radical Radiotherapy in Sinonasal Myopericytoma: A Case Report and Literature Overview
Anna Merlotti, Stefania Martini, Riccardo Vigna Taglianti, Alessia Reali, Giuseppe Signorini, Silvana Parisi, Francesca De Felice
EMJ Oncology.2023;[Epub] CrossRef
Intracranial Solitary Fibrous Tumour Management: A French Multicentre Retrospective Study
Marine Lottin, Alexandre Escande, Luc Bauchet, Marie Albert-Thananayagam, Maël Barthoulot, Matthieu Peyre, Mathieu Boone, Sonia Zouaoui, Jacques Guyotat, Guillaume Penchet, Johan Pallud, Henry Dufour, Evelyne Emery, Michel Lefranc, Sébastien Freppel, Houm
Cancers.2023; 15(3): 704. CrossRef
Solitary fibrous tumor of the central nervous system invading and penetrating the skull: A case report
Qiyan Lin, Jiabin Zhu, Xiaofeng Zhang
Oncology Letters.2023;[Epub] CrossRef
Impact of extent of resection and postoperative radiotherapy on survival outcomes in intracranial solitary fibrous tumors: a systematic review and meta-analysis
Sae Min Kwon, Min Kyun Na, Kyu-Sun Choi, Tae Ho Lim, Hyungoo Shin, Juncheol Lee, Heekyung Lee, Wonhee Kim, Youngsuk Cho, Jae Guk Kim, Chiwon Ahn, Bo-Hyoung Jang
Neurosurgical Review.2023;[Epub] CrossRef
Radiotherapy for rare primary brain tumors
E. Mesny, P. Lesueur
Cancer/Radiothérapie.2023; 27(6-7): 599. CrossRef
Complete Resection of a Torcular Herophili Hemangiopericytoma without Sinus Reconstruction: A Case Report and Review of the Literature
Salah-Edine Safi, Julie Godfrain, Herbert Rooijakkers, Frederic Collignon, Mario Ganau
Case Reports in Surgery.2023; 2023: 1. CrossRef
Surgical Management of Craniospinal Axis Solitary Fibrous Tumors: A Single-Institution Case Series and Comprehensive Review of the Literature
Anthony J. Piscopo, A. J. Chowdhury, Nahom Teferi, Sarah Lee, Meron Challa, Michael Petronek, Kathryn Eschbacher, Girish Bathla, John M. Buatti, Patrick Hitchon
Neurosurgery.2023;[Epub] CrossRef
Clinical Features, Management, and Prognostic Factors of Intracranial Solitary Fibrous Tumor
Jingdian Liu, Sisi Wu, Kai Zhao, Junwen Wang, Kai Shu, Ting Lei
Frontiers in Oncology.2022;[Epub] CrossRef
Toward Better Understanding and Management of Solitary Fibrous Tumor
Karineh Kazazian, Elizabeth G. Demicco, Marc de Perrot, Dirk Strauss, Carol J. Swallow
Surgical Oncology Clinics of North America.2022; 31(3): 459. CrossRef
Effect of Different Treatments for Intracranial Solitary Fibrous Tumors: Retrospective Analysis of 31 Patients
Qinghua Li, Wenshuai Deng, Peng Sun
World Neurosurgery.2022; 166: e60. CrossRef
Sixteen-Year Follow-Up in a Cavernous Sinus Hemangiopericytoma: Improved Outcomes over Radiotherapy Advances
Beatrice Detti, Lilia Bardoscia, Antonio Rosario Pisani, Salvatore Cozzi, Manuele Roghi, Paolo Mammucci, Angela Sardaro
Brain Sciences.2022; 12(9): 1209. CrossRef
Solitary Fibrous Tumor of the Jugular Foramen: A Case Report and Review of the Histopathologic Classification
Mallory Raymond, Philip Ryan Elvis, Tiffany Baker, William Alexander Vandergrift, Theodore McRackan
Otology & Neurotology.2022; 43(10): e1208. CrossRef
A Comprehensive Review on Solitary Fibrous Tumor: New Insights for New Horizons
Javier Martin-Broto, Jose L. Mondaza-Hernandez, David S. Moura, Nadia Hindi
Cancers.2021; 13(12): 2913. CrossRef
Intradural Extramedullary Solitary Fibrous Tumor of the Thoracic Spinal Cord
Zachary T Olmsted, Joanna Tabor, Omer Doron, Hossein Hosseini, Daniel Schneider, Ross Green, Samuel J Wahl, Daniel M Scuibba, Randy S D'Amico
Cureus.2021;[Epub] CrossRef

8,686 View
343 Download
19 Web of Science
22 Crossref

Central nervous system

Clinical and Genomic Characteristics of Adult Diffuse Midline Glioma: Changhee Park, Tae Min Kim, Jeong Mo Bae, Hongseok Yun, Jin Wook Kim, Seung Hong Choi, Soon-Tae Lee, Joo Ho Lee, Sung-Hye Park, Chul-Kee Park; Cancer Res Treat. 2021;53(2):389-398. Published online November 9, 2020; DOI: https://doi.org/10.4143/crt.2020.694

Abstract PDF Supplementary Material PubReader ePub

Purpose
The treatment outcomes and genomic profiles of diffuse midline glioma (DMG) in adult patients are rarely characterized. We performed a retrospective study to evaluate the clinicogenomic profiles of adult patients with brain DMG.
Materials and Methods
Patients aged ≥ 18 years diagnosed with brain DMG at Seoul National University Hospital were included. The clinicopathological parameters, treatment outcomes, survival, and genomic profiles using 82-gene targeted next-generation sequencing (NGS) were analyzed. The 6-month progression-free survival (PFS6) after radiotherapy and overall survival (OS) were evaluated.
Results
Thirty-three patients with H3-mutant brain DMG were identified. The median OS from diagnosis was 21.8 months (95% confidence interval [CI], 13.2 to not available [NA]) and involvement of the ponto-medullary area tended to have poor OS (median OS, 20.4 months [95% CI, 9.3 to NA] vs. 43.6 months [95% CI, 18.2 to NA]; p=0.07). Twenty-four patients (72.7%) received radiotherapy with or without temozolomide. The PFS6 rate was 83.3% (n=20). Patients without progression at 6 months showed significantly prolonged OS compared with those with progression at 6 months (median OS, 24.9 months [95% CI, 20.4 to NA] vs. 10.8 months [95% CI, 4.0 to NA]; p=0.02, respectively). Targeted NGS was performed in 13 patients with DMG, among whom nine (69.2%) harbored concurrent TP53 mutation. Two patients (DMG14 and DMG23) with PIK3CA^R38S+E545K and KRAS^G12A mutations received matched therapies. Patient DMG14 received sirolimus with a PFS of 8.4 months.
Conclusion
PFS6 after radiotherapy was associated with prolonged survival in adult patients with DMG. Genome-based matched therapy may be an encouraging approach for progressive adult patients with DMG.

Citations

Citations to this article as recorded by

The role of adjuvant chemotherapy in patients with H3K27 altered diffuse midline gliomas: a multicentric retrospective study
Vincenzo Di Nunno, Giuseppe Lombardi, Matteo Simonelli, Giuseppe Minniti, Angela Mastronuzzi, Valentina Di Ruscio, Martina Corrà, Marta Padovan, Marta Maccari, Mario Caccese, Giorgia Simonetti, Arianna Berlendis, Mariangela Farinotti, Bianca Pollo, Manila
Journal of Neuro-Oncology.2024; 167(1): 145. CrossRef
Neuroradiological, genetic and clinical characteristics of histone H3 K27-mutant diffuse midline gliomas in the Kansai Molecular Diagnosis Network for CNS Tumors (Kansai Network): multicenter retrospective cohort
Nobuhide Hayashi, Junya Fukai, Hirokazu Nakatogawa, Hiroshi Kawaji, Ema Yoshioka, Yoshinori Kodama, Kosuke Nakajo, Takehiro Uda, Kentaro Naito, Noriyuki Kijima, Yoshiko Okita, Naoki Kagawa, Yoshinobu Takahashi, Naoya Hashimoto, Hideyuki Arita, Koji Takano
Acta Neuropathologica Communications.2024;[Epub] CrossRef
Genetic alteration analysis of non-pediatric diffuse midline glioma, H3 K27-altered
Hanbin Jang, Seyoung Moon, Hyun Jung Kwon, Sejoon Lee, Gheeyoung Choe, Kyu Sang Lee
Human Pathology.2024; 154: 105709. CrossRef
How to treat histone 3 altered gliomas: molecular landscape and therapeutic developments
Vincenzo Di Nunno, Enrico Franceschi, Lidia Gatto, Alicia Tosoni, Stefania Bartolini, Alba Ariela Brandes
Expert Review of Clinical Pharmacology.2023; 16(1): 17. CrossRef
Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
Kwanghoon Lee, Seong-Ik Kim, Eric Eunshik Kim, Yu-Mi Shim, Jae-Kyung Won, Chul-Kee Park, Seung Hong Choi, Hongseok Yun, Hyunju Lee, Sung-Hye Park
Scientific Reports.2023;[Epub] CrossRef
Radiotherapy and radio‐sensitization in H3K27M‐mutated diffuse midline gliomas
Chao Liu, Shuwen Kuang, Lei Wu, Quan Cheng, Xuan Gong, Jun Wu, Longbo Zhang
CNS Neuroscience & Therapeutics.2023; 29(7): 1721. CrossRef
Volumetric response and pattern of failure of histone altered high grade glioma in adults following management with radiation therapy
A. Knight, P. Horsley, A. Yuile, J. Yim, M. Suh, V. Venketesha, M. Kastelan, H. Wheeler, M. Back
Journal of Neuro-Oncology.2023; 163(1): 281. CrossRef
Differences in survival prognosticators between children and adults with H3K27M‐mutant diffuse midline glioma
Xuan Gong, Shuwen Kuang, Dongfeng Deng, Jun Wu, Longbo Zhang, Chao Liu
CNS Neuroscience & Therapeutics.2023; 29(12): 3863. CrossRef
Adult spinal cord diffuse midline glioma, H3 K27-altered mimics symptoms of central nervous system infection: a case report
Xue Chen, Yi Li, Hui Bu, YueLi Zou, JunYing He, Hu Liu
Frontiers in Neurology.2023;[Epub] CrossRef
Clinicogenetic characteristics and the effect of radiation on the neural stem cell niche in subventricular zone-contacting glioblastoma
Jee Ye Kahng, Byung-Hee Kang, Soon-Tae Lee, Seung Hong Choi, Tae Min Kim, Chul-Kee Park, Jae-Kyung Won, Sung-Hye Park, Jaeman Son, Joo Ho Lee
Radiotherapy and Oncology.2023; 186: 109800. CrossRef
H3 K27M-Altered Diffuse Midline Gliomas: A Review
Karol Wiśniewski, Andrew Ghaly, Kate Drummond, Andreas Fahlstrӧm
Indian Journal of Neurosurgery.2023; 12(02): 104. CrossRef
Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity
Carlos Axel López-Pérez, Xochitl Franco-Mojica, Ricardo Villanueva-Gaona, Alexandra Díaz-Alba, Marco Antonio Rodríguez-Florido, Victor Garcia Navarro
Journal of Neuro-Oncology.2022; 158(3): 369. CrossRef
H3K27M-Altered Diffuse Midline Gliomas Among Adult Patients: A Systematic Review of Clinical Features and Survival Analysis
Othman Bin-Alamer, Adrian E. Jimenez, Tej D. Azad, Chetan Bettegowda, Debraj Mukherjee
World Neurosurgery.2022; 165: e251. CrossRef
Molecular profile and clinical features of patients with gliomas using a broad targeted next generation‑sequencing panel
Ourania Romanidou, Paraskevi Apostolou, Kyriakos Kouvelakis, Kyriakos Tsangaras, Alexia Eliades, Achilleas Achilleos, Charalambos Loizides, Christos Lemesios, Marios Ioannides, Elena Kypri, George Koumbaris, Kyriaki Papadopoulou, Athanasios Papathanasiou,
Oncology Letters.2022;[Epub] CrossRef

8,549 View
229 Download
14 Web of Science
14 Crossref

Underexpression of HOXA11 Is Associated with Treatment Resistance and Poor Prognosis in Glioblastoma: Young-Bem Se, Seung Hyun Kim, Ji Young Kim, Ja Eun Kim, Yun-Sik Dho, Jin Wook Kim, Yong Hwy Kim, Hyun Goo Woo, Se-Hyuk Kim, Shin-Hyuk Kang, Hak Jae Kim, Tae Min Kim, Soon-Tae Lee, Seung Hong Choi, Sung-Hye Park, Il Han Kim, Dong Gyu Kim, Chul-Kee Park; Cancer Res Treat. 2017;49(2):387-398. Published online July 19, 2016; DOI: https://doi.org/10.4143/crt.2016.106

Abstract PDF Supplementary Material PubReader ePub

Purpose
Homeobox (HOX) genes are essential developmental regulators that should normally be in the silenced state in an adult brain. The aberrant expression of HOX genes has been associated with the prognosis of many cancer types, including glioblastoma (GBM). This study examined the identity and role of HOX genes affecting GBM prognosis and treatment resistance.
Materials and Methods
The full series of HOX genes of five pairs of initial and recurrent human GBM samples were screened by microarray analysis to determine the most plausible candidate responsible for GBM prognosis. Another 20 newly diagnosed GBM samples were used for prognostic validation. In vitro experiments were performed to confirm the role of HOX in treatment resistance. Mediators involved in HOX gene regulation were searched using differentially expressed gene analysis, gene set enrichment tests, and network analysis.
Results
The underexpression of HOXA11 was identified as a consistent signature for a poor prognosis among the HOX genes. The overall survival of the GBM patients indicated a significantly favorable prognosis in patients with high HOXA11 expression (31±15.3 months) compared to the prognoses in thosewith lowHOXA11 expression (18±7.3 months, p=0.03). When HOXA11 was suppressed in the GBM cell lines, the anticancer effect of radiotherapy and/or temozolomide declined. In addition, five candidate mediators (TGFBR2, CRIM1, TXNIP, DPYSL2, and CRMP1) that may confer an oncologic effect after HOXA11 suppression were identified.
Conclusion
The treatment resistance induced by the underexpression of HOXA11 can contribute to a poor prognosis in GBM. Further investigation will be needed to confirm the value of HOXA11 as a potential target for overcoming the treatment resistance by developing chemo- or radiosensitizers.

Citations

Citations to this article as recorded by

Intratumoral IL-12 delivery via mesenchymal stem cells combined with PD-1 blockade leads to long-term antitumor immunity in a mouse glioblastoma model
Junseong Park, Soon A. Park, Yoon-Seob Kim, Dokyeong Kim, Sun Shin, Sug Hyung Lee, Sin-Soo Jeun, Yeun-Jun Chung, Stephen Ahn
Biomedicine & Pharmacotherapy.2024; 173: 115790. CrossRef
Dihydropyrimidinase‐like 2 can serve as a novel therapeutic target and prognostic biomarker in acute myeloid leukemia
Fenglin Li, Qing Ling, Jiaying Lian, Ying Chen, Chao Hu, Min Yang, Xiang Zhang, Chenying Li, Shihui Mao, Wenle Ye, Xia Li, Xiangjie Lin, Wenwen Wei, Xin Huang, Jiajia Pan, Yu Qian, Jinghan Wang, Ying Lu, Jie Jin
Cancer Medicine.2023; 12(7): 8319. CrossRef
Development and validation of a predictive model in diagnosis and prognosis of primary glioblastoma patients based on Homeobox A family
Zong-Qing Zheng, Gui-Qiang Yuan, Guo-Guo Zhang, Qian-Qian Nie, Zhong Wang
Discover Oncology.2023;[Epub] CrossRef
HOXA11-AS aggravates microglia-induced neuroinflammation after traumatic brain injury
Xiang-Long Li, Bin Wang, Fu-Bing Yang, Li-Gang Chen, Jian You
Neural Regeneration Research.2022; 17(5): 1096. CrossRef
Molecular implications of HOX genes targeting multiple signaling pathways in cancer
U Sangeetha Shenoy, Divya Adiga, Shama Prasada Kabekkodu, Keith D Hunter, Raghu Radhakrishnan
Cell Biology and Toxicology.2022; 38(1): 1. CrossRef
High expression ofHOXA4in patients with glioma indicates unfavorable clinical outcomes
Zhenghong Yu, Zhendong Liu, Xiaoyu Lian, Xingbo Cheng, Binfeng Liu, Bo Zhang, Hongbo Wang, Jialin Wang, Ang Li, Zhishuai Ren, Bo Pang, Rongjun Qian, Yanzheng Gao
Cell Cycle.2022; 21(22): 2387. CrossRef
Downregulation of HOXA11 enhances endometrial cancer malignancy and cisplatin resistance via activating PTEN/AKT signaling pathway
C. Kong, Z. Zhu, Y. Li, P. Xue, L. Chen
Clinical and Translational Oncology.2021; 23(7): 1334. CrossRef
Long Non-Coding RNAs in Diagnosis, Treatment, Prognosis, and Progression of Glioma: A State-of-the-Art Review
Sara Momtazmanesh, Nima Rezaei
Frontiers in Oncology.2021;[Epub] CrossRef
Molecular Biomarkers for Lung Adenocarcinoma: A Short Review
Srikumar Chakravarthi, Barani Karikalan
Current Cancer Therapy Reviews.2021; 17(2): 97. CrossRef
HOX gene cluster (de)regulation in brain: from neurodevelopment to malignant glial tumours
Céline S. Gonçalves, Elisa Le Boiteux, Philippe Arnaud, Bruno M. Costa
Cellular and Molecular Life Sciences.2020; 77(19): 3797. CrossRef
Expression Profile and Prognostic Values of HOXA Family Members in Laryngeal Squamous Cell Cancer
Jinyun Li, Meng Ye, Chongchang Zhou
Frontiers in Oncology.2020;[Epub] CrossRef
Methylation in HOX Clusters and Its Applications in Cancer Therapy
Ana Paço, Simone Aparecida de Bessa Garcia, Renata Freitas
Cells.2020; 9(7): 1613. CrossRef
N6-Methylandenosine-Related lncRNAs Are Potential Biomarkers for Predicting the Overall Survival of Lower-Grade Glioma Patients
Zewei Tu, Lei Wu, Peng Wang, Qing Hu, Chuming Tao, Kuangxun Li, Kai Huang, Xingen Zhu
Frontiers in Cell and Developmental Biology.2020;[Epub] CrossRef
Targeting HOX/PBX dimer formation as a potential therapeutic option in esophageal squamous cell carcinoma
Lu‐Yan Shen, Ting Zhou, Ya‐Bing Du, Qi Shi, Ke‐Neng Chen
Cancer Science.2019; 110(5): 1735. CrossRef
An inverse interaction betweenHOXA11andHOXA11-ASis associated with cisplatin resistance in lung adenocarcinoma
Youwei Zhang, Yuan Yuan, Yang Li, Peiying Zhang, Pingsheng Chen, Sanyuan Sun
Epigenetics.2019; 14(10): 949. CrossRef
Long noncoding RNA HOXA11-AS promotes gastric cancer cell proliferation and invasion via SRSF1 and functions as a biomarker in gastric cancer
Yun Liu, Yu-Mei Zhang, Feng-Bo Ma, Su-Rong Pan, Bao-Zhen Liu
World Journal of Gastroenterology.2019; 25(22): 2763. CrossRef
DNA methylation changes following DNA damage in prostate cancer cells
Laura P. Sutton, Sarah A. Jeffreys, Jessica L. Phillips, Phillippa C. Taberlay, Adele F. Holloway, Mark Ambrose, Ji-Hoon E. Joo, Arabella Young, Rachael Berry, Marketa Skala, Kate H. Brettingham-Moore
Epigenetics.2019; 14(10): 989. CrossRef
MicroRNA‐128/homeobox B8 axis regulates ovarian cancer cell progression
Rui Li, Lingling Gong, Pin Li, Jing Wang, Liangliang Bi
Basic & Clinical Pharmacology & Toxicology.2019; 125(6): 499. CrossRef
Evaluation of the HOXA11 level in patients with lung squamous cancer and insights into potential molecular pathways via bioinformatics analysis
Rui Zhang, Tong-tong Zhang, Gao-qiang Zhai, Xian-yu Guo, Yuan Qin, Ting-qing Gan, Yu Zhang, Gang Chen, Wei-jia Mo, Zhen-bo Feng
World Journal of Surgical Oncology.2018;[Epub] CrossRef
HOXA11 antisense long noncoding RNA (HOXA11‐AS): A promising lncRNA in human cancers
Cheng‐Wei Lu, Dan‐Dan Zhou, Tian Xie, Ji‐Long Hao, Om Prakash Pant, Cheng‐Bo Lu, Xiu‐Fen Liu
Cancer Medicine.2018; 7(8): 3792. CrossRef
Identification of radiation responsive genes and transcriptome profiling via complete RNA sequencing in a stable radioresistant U87 glioblastoma model
Ninh B. Doan, Ha S. Nguyen, Hisham S. Alhajala, Basem Jaber, Mona M. Al-Gizawiy, Eun-Young Erin Ahn, Wade M. Mueller, Christopher R. Chitambar, Shama P. Mirza, Kathleen M. Schmainda
Oncotarget.2018; 9(34): 23532. CrossRef
Upregulation of HOXA11 during the progression of lung adenocarcinoma detected via multiple approaches
Xia Yang, Yun Deng, Rong‑Quan He, Xiao‑Jiao Li, Jie Ma, Gang Chen, Xiao‑Hua Hu
International Journal of Molecular Medicine.2018;[Epub] CrossRef
Clinical Significance and Effect of lncRNA HOXA11-AS in NSCLC: A Study Based on Bioinformatics, In Vitro and in Vivo Verification
Yu Zhang, Wen-jie Chen, Ting-qing Gan, Xiu-ling Zhang, Zu-cheng Xie, Zhi-hua Ye, Yun Deng, Ze-feng Wang, Kai-teng Cai, Shi-kang Li, Dian-zhong Luo, Gang Chen
Scientific Reports.2017;[Epub] CrossRef
Functional analysis of HOXA10 and HOXB4 in human medulloblastoma cell lines
Ricardo Bonfim-Silva, Fernanda Ursoli Ferreira Melo, Carolina Hassibe Thomé, Kuruvilla Joseph Abraham, Fábio Augusto Labre De Souza, Fernando Silva Ramalho, Hélio Rubens Machado, Ricardo Santos De Oliveira, Angelo A. Cardoso, Dimas Tadeu Covas, Aparecida
International Journal of Oncology.2017; 51(6): 1929. CrossRef
Long non-coding RNA HOXA11-AS promotes cell proliferation and metastasis in human breast cancer
Jian-Chun Su, Xue-Feng Hu
Molecular Medicine Reports.2017; 16(4): 4887. CrossRef
Identification of skin-related lncRNAs as potential biomarkers that are involved in Wnt pathways in keloids
Xiao-Jie Sun, Qiang Wang, Baofeng Guo, Xian-Ying Liu, Bing Wang
Oncotarget.2017; 8(21): 34236. CrossRef
Microarray-based analysis and clinical validation identify ubiquitin-conjugating enzyme E2E1 (UBE2E1) as a prognostic factor in acute myeloid leukemia
Hongmei Luo, Yu Qin, Frederic Reu, Sujuan Ye, Yang Dai, Jingcao Huang, Fangfang Wang, Dan Zhang, Ling Pan, Huanling Zhu, Yu Wu, Ting Niu, Zhijian Xiao, Yuhuan Zheng, Ting Liu
Journal of Hematology & Oncology.2016;[Epub] CrossRef

14,787 View
330 Download
30 Web of Science
27 Crossref

Extra-cranial Malignant Rhabdoid Tumor in Children: A Single Institute Experience: Che Ry Hong, Hyoung Jin Kang, Hee Young Ju, Ji Won Lee, Hyery Kim, Sung-Hye Park, Il Han Kim, Kyung Duk Park, Hee Young Shin; Cancer Res Treat. 2015;47(4):889-896. Published online January 2, 2015; DOI: https://doi.org/10.4143/crt.2013.176

Abstract PDF PubReader ePub

Purpose
Malignant rhabdoid tumor (MRT) is a rare and highly aggressive tumor that affects young children. Due to its extreme rarity, most of the available data are based on retrospective case series. To add to the current knowledge of this disease, we reviewed the patients treated for extra-cranial MRT in our institute. Materials and Methods A retrospective medical record review was conducted on children treated for pathologically confirmed extra-cranial MRT at Seoul National University Children’s Hospital between January 2003 and May 2013. Results Eleven patients (7 boys, 4 girls) were diagnosed with extra-cranial MRT at a median age of 9 months old. INI1 staining was important in the pathological confirmation. Six patients (55%) had renal MRT and five (45%) had soft tissue MRT. Five patients (45%) had metastases at diagnosis. All patients underwent chemotherapy, eight patients (73%) underwent surgery, six patients (55%) received therapeutic radiotherapy, and four patients (36%) underwent high dose chemotherapy with autologous stem cell rescue (HDCT/ASCR) with melphalan, etoposide, and carboplatin. Five patients (45%) died of disease following progression (n=3) or relapse (n=2), however, there was no treatment related mortality. The overall survival of the cohort was 53.0% and the event-free survival was 54.5% with a median follow-up duration of 17.8 months (range, 2.3 to 112.3 months). Conclusion Extra-cranial MRT is still a highly aggressive tumor in young children. However, the improved survival of our cohort is promising and HDCT/ASCR with melphalan, etoposide, and carboplatin may be a promising treatment option.

Citations

Citations to this article as recorded by

Extracranial malignant rhabdoid tumors in children: high mortality even with the help of an aggressive clinical approach
Siqi Xie, Yuanyuan Fang, Yingying Yang, Lan Liu, Jianxi Bai, Sheng Lin, Bing Zhang, Yifan Fang
European Journal of Pediatrics.2023; 183(2): 557. CrossRef
Infantile Extracranial Rhabdoid Tumor of the Scalp
Sura Al Rawabdeh, Deifallah Alsharari, Hayat Khasawneh, Ola M. Al Waqfi, Qamar Yaser Malabeh, Hiathem Abu Alhaija, Raed Mohammad Aljubour, Hamzeh M. Alkhawaldeh, Pablo Fernandez Pe as
Case Reports in Medicine.2021; 2021: 1. CrossRef
Pharmacokinetics of high-dose carboplatin in children undergoing high-dose chemotherapy and autologous stem cell transplantation with BSA-based dosing
Che Ry Hong, Hyoung Jin Kang, Seol Ju Moon, Jaeseong Oh, Kyung Taek Hong, Jung Yoon Choi, Kyung-Sang Yu, Hee Young Shin
Bone Marrow Transplantation.2020; 55(1): 137. CrossRef
Successful Treatment of Extra‐Renal Noncerebral Rhabdoid Tumors with VIDE
Naoko Yasui, Akihiko Yoshida, Eisuke Kobayashi, Fumihiko Nakatani, Hiroshi Kawamoto
Pediatric Blood & Cancer.2016; 63(2): 352. CrossRef

14,558 View
149 Download
5 Web of Science
4 Crossref

Low-Dose Whole Brain Radiotherapy with Tumor Bed Boost after Methotrexate-Based Chemotherapy for Primary Central Nervous System Lymphoma: Byoung Hyuck Kim, Il Han Kim, Sung-Hye Park, Chul Kee Park, Hee Won Jung, Tae Min Kim, Se-Hoon Lee, Dae Seog Heo; Cancer Res Treat. 2014;46(3):261-269. Published online July 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.3.261

Abstract PDF PubReader ePub

Purpose
The purpose of this study is to evaluate the outcome of low-dose whole brain radiotherapy (WBRT) with tumor bed boost after methotrexate-based chemotherapy in the management of primary central nervous system lymphoma (PCNSL). Materials and Methods We retrospectively analyzed 64 patients with pathologically proven PCNSL between 2000 and 2011. Methotrexate-based chemotherapy with a median of five cycles was followed by radiotherapy to the whole brain and to the initial tumor bed. The median dose to the whole brain and to the tumor bed was 27 Gy (range, 18 to 36 Gy) and 50.4 Gy (range, 45 to 54 Gy), respectively. Results With a median follow-up period of 27 months, 55 patients (85.9%) achieved complete response (CR). The 5-year overall survival (OS) and progression-free survival (PFS) rates were 52.6% and 39.3%, respectively. In univariate analysis, factors associated with OS were age, performance status, involvement of deep structure, and CR to sequential chemoradiotherapy (CRT). These variables remained as significant factors for OS in multivariate analysis. CR to sequential CRT was the only positive factor associated with PFS (p=0.009). Neurologic toxicity was more common in elderly patients older than 60 years (p=0.025). Conclusion Low-dose WBRT with tumor bed boost after methotrexate-based chemotherapy might be an effective method for management of PCNSL.

Citations

Citations to this article as recorded by

A narrative review of consolidation strategies for young and fit patients with newly-diagnosed primary central nervous system lymphoma
Sara Steffanoni, Teresa Calimeri, Nicoletta Anzalone, Sara Mastaglio, Massimo Bernardi, Andrés JM Ferreri
Expert Review of Hematology.2022; 15(1): 33. CrossRef
Analysis of Key Factors Associated with Response to Salvage High-Dose Methotrexate Rechallenge in Primary Central Nervous System Lymphoma with First Relapse
Peng Du, Hongyi Chen, Li Shen, Xiao Liu, Xuefan Wu, Lang Chen, Aihong Cao, Daoying Geng
Current Oncology.2022; 29(9): 6642. CrossRef
Cytoreductive Surgery for Primary Central Nervous System Lymphoma: Is it time to consider extent of resection?
Shaani Singhal, Ellathios Antoniou, Edward Kwan, Gareth Gregory, Leon T. Lai
Journal of Clinical Neuroscience.2022; 106: 110. CrossRef
Role of 23.4 Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy
Nalee Kim, Do Hoon Lim, Sang Eun Yoon, Seok Jin Kim, Won Seog Kim
Journal of Neuro-Oncology.2021; 154(2): 207. CrossRef
Nanomedicine Applications in Treatment of Primary Central Nervous System Lymphoma: Current State of the Art
Mengyao Wang, Ying Qu, Danrong Hu, Ting Niu, Zhiyong Qian
Journal of Biomedical Nanotechnology.2021; 17(8): 1459. CrossRef
Reduced-dose whole-brain radiotherapy with tumor bed boost after upfront high-dose methotrexate for primary central nervous system lymphoma
Tae Hoon Lee, Joo Ho Lee, Ji Hyun Chang, Sung-Joon Ye, Tae Min Kim, Chul-Kee Park, Il Han Kim, Byoung Hyuck Kim, Chan Woo Wee
Radiation Oncology Journal.2020; 38(1): 35. CrossRef
Advances and challenges in the treatment of primary central nervous system lymphoma
Hua Yang, Yang Xun, Anping Yang, Fang Liu, Hua You
Journal of Cellular Physiology.2020; 235(12): 9143. CrossRef
Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy
Jun Su Park, Do Hoon Lim, Yong Chan Ahn, Won Park, Seok Jin Kim, Won Seog Kim, Kihyun Kim
Japanese Journal of Clinical Oncology.2017; 47(11): 995. CrossRef
Role of radiation therapy in primary central nervous system lymphoma
Hyeon Kang Koh, Il Han Kim, Tae Min Kim, Do Hoon Lim, Dongryul Oh, Jae Ho Cho, Woo-Chul Kim, Jin Hee Kim, Woong-Ki Chung, Bae-Kwon Jeong, Ki Mun Kang, Semie Hong, Chang-Ok Suh, In Ah Kim
Journal of Neuro-Oncology.2017; 135(3): 629. CrossRef

12,572 View
77 Download
10 Web of Science
9 Crossref

Clinical Characteristics and Treatment Results of Pediatric Osteosarcoma: The Role of High Dose Chemotherapy with Autologous Stem Cell Transplantation: Ji Won Lee, Hyery Kim, Hyoung Jin Kang, Han-Soo Kim, Sung-Hye Park, In-One Kim, Hyo Seop Ahn, Hee Young Shin; Cancer Res Treat. 2008;40(4):172-177. Published online December 31, 2008; DOI: https://doi.org/10.4143/crt.2008.40.4.172

Abstract PDF PubReader ePub

Purpose

In this study, we investigated the clinical characteristics and treatment results of osteosarcoma during the past 7 years, and evaluated the role of high dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT).

Materials and Methods

We retrospectively analyzed the clinical data of patients who were diagnosed as osteosarcoma at our center from January, 2000 to December, 2007.

Results

The 5-year overall survival and event-free survival of the patients were 72.6% and 55.9%, respectively. Seventeen (41.5%) patients showed disease progression during treatment or relapse after the end of treatment. The patients who had metastasis at diagnosis or who had a lower grade of necrosis after neoadjuvant chemotherapy showed decreased overall and event-free survival. Four patients received ASCT after HDCT, and 3 of them are alive without disease.

Conclusions

The patients who relapsed or had refractory osteosarcoma or who had metastasis at diagnosis or a lower grade of necrosis after neoadjuvant chemotherapy showed poor prognosis. HDCT with ASCT could be an alternative treatment option for these patients.

Citations

Citations to this article as recorded by

High‐dose chemotherapy followed by autologous stem cell transplantation in pediatric patients with relapsed osteosarcoma
Sung Han Kang, Wanlim Kim, Jong Seok Lee, Jin Kyung Suh, Hyery Kim, Dong Kwan Kim, Se Hoon Choi, Hee Won Cho, Hee Young Ju, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Sung Wook Seo, Ho Joon Im, Ji Won Lee, Kyung‐Nam Koh
Pediatric Blood & Cancer.2023;[Epub] CrossRef
Favorable outcome of high-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with nonmetastatic osteosarcoma and low-degree necrosis
Kyung Taek Hong, Hyun Jin Park, Bo Kyung Kim, Hong Yul An, Jung Yoon Choi, Jung-Eun Cheon, Sung-Hye Park, Han-Soo Kim, Hyoung Jin Kang
Frontiers in Oncology.2022;[Epub] CrossRef
The Outcome of Children With Malignant Bone Tumors: A Single-Center Experience
Mohammadreza Bordbar, Ali Sarfaraz, Sezaneh Haghpanah, Omidreza Zekavat, Soheila Zareifar, Tahereh Zarei
Global Pediatric Health.2021;[Epub] CrossRef
1
L.V. Hryvkova
Practical oncology.2021; 4(1): 30. CrossRef
Retrospective analysis of high-dose chemotherapy followed by autologous stem cell transplantation for high-risk pediatric osteosarcoma
Suguru Uemura, Takeshi Mori, Shinya Ishiko, Satoru Takafuji, Nanako Nino, Nobuyuki Yamamoto, Akira Hayakawa, Noriyuki Nishimura, Hitomi Hara, Teruya Kawamoto, Toshihiro Akisue, Kazumoto Iijima
Pediatric Hematology and Oncology.2020; 37(4): 337. CrossRef
Pulmonary tuberculosis mimicking radiation pneumonitis in a patient with neck malignancy
Kyungsoo Bae, Kyung Nyeo Jeon, Hoon Sik Choi, Dae Hyun Song, Ho Cheol Kim
Medicine.2019; 98(27): e16398. CrossRef
High-dose chemotherapy and autologous stem cell transplantation with melphalan, etoposide and carboplatin for high-risk osteosarcoma
C R Hong, H J Kang, M S Kim, H Y Ju, J W Lee, H Kim, H-S Kim, S-H Park, K D Park, J D Park, H Y Shin, H S Ahn
Bone Marrow Transplantation.2015; 50(10): 1375. CrossRef
High‐dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: Final results of the ISG/SSG II study
Kjetil Boye, Adalberto Brach Del Prever, Mikael Eriksson, Gunnar Sæter, Amelia Tienghi, Paula Lindholm, Franca Fagioli, Sigmund Skjeldal, Stefano Ferrari, Kirsten Sundby Hall
Pediatric Blood & Cancer.2014; 61(5): 840. CrossRef
LY294002 suppresses the malignant phenotype and sensitizes osteosarcoma cells to pirarubicin chemotherapy
XIN HUA LONG, ZHEN HAO ZHONG, AI FEN PENG, LIANG BO ZHU, HENG WANG, GUO MEI ZHANG, ZHI LI LIU
Molecular Medicine Reports.2014; 10(6): 2967. CrossRef
Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma
Colin Moore, Don Eslin, Alejandro Levy, Jessica Roberson, Vincent Giusti, Robert Sutphin
Pediatric Blood & Cancer.2010; 55(6): 1096. CrossRef
Cryoimmunologic Antitumor Effects Enhanced by Dendritic Cells in Osteosarcoma
Masanori Kawano, Hideji Nishida, Yasunari Nakamoto, Hiroshi Tsumura, Hiroyuki Tsuchiya
Clinical Orthopaedics and Related Research®.2010; 468(5): 1373. CrossRef

10,248 View
67 Download
11 Crossref

First
Prev
Page of 1
Next
Last

Search